ABIVAX press release
Abivax completes treatment of last patient in phase 2b induction study in ulcerative colitis.
End of 16-week induction treatment in 254 patients in the phase 2b clinical study with ABX464 for the treatment of ulcerative colitis, with reduction in the total Mayo score after 8 weeks as the primary endpoint.
First results of the induction study available during the second half of May 2021.
Inclusion of patients in the phase 2b maintenance study with ABX464 administered for 48 weeks in ulcerative colitis now complete, with first results expected in the first quarter of 2022.
Start of the phase 3 clinical program in ulcerative colitis expected at the end of this year.
Key Opinion Leader webcast presentation scheduled for Tuesday, April 20, 2021 at 1:30 p.m. CEST with Professor Bruce Sands, MD, MS, on proctocolitis
bleeding, existing and future treatments, and unmet medical needs.
– .
